CD8A and neoplasm: While increasing the number of infiltrating immune cells in tumor microenvironment, bortezomib also displayed ability of enhancing the antitumor function of CD8+ T cells through miR-155-SOCS1/SHIP1-T-bet-PD1 axis (Renrick et al., 2021).